Poseida Therapeutics, Inc. (PSTX) Bundle
An Overview of Poseida Therapeutics, Inc. (PSTX)
General Summary of Poseida Therapeutics, Inc. (PSTX)
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies for high-unmet medical needs.
- Founded in 2014 and headquartered in San Diego, California
- Specializes in developing cell and gene therapies
- Primary focus areas: oncology and rare diseases
Key product pipeline includes:
| Product | Indication | Development Stage |
|---|---|---|
| P-BCMA-ALLO1 | Multiple Myeloma | Phase 1/2 Clinical Trial |
| P-MUC1C-ALLO1 | Solid Tumors | Preclinical Stage |
Financial Performance in Latest Reporting Period
Financial highlights for fiscal year 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $18.4 million |
| Research & Development Expenses | $93.2 million |
| Net Loss | $106.3 million |
| Cash and Cash Equivalents | $220.5 million |
Industry Leadership
Poseida Therapeutics demonstrates leadership through:
- Proprietary gene editing technologies
- Advanced CAR-T cell therapy platforms
- Innovative approaches to allogeneic cell therapies
The company's unique PiggyBac DNA Modification System provides competitive advantages in cell and gene therapy development.
Mission Statement of Poseida Therapeutics, Inc. (PSTX)
Mission Statement Overview of Poseida Therapeutics, Inc. (PSTX)
Poseida Therapeutics, Inc. (PSTX) focuses on developing transformative cell and gene therapies targeting serious diseases with high unmet medical needs.
Core Components of Mission Statement
Innovative Gene Editing Technology
Poseida utilizes proprietary gene editing technologies, including:
- PIus™ Gene Editing Platform
- NextT™ Cell Therapy Platform
- Booster™ CAR-T Technology
Research and Development Investment
| Fiscal Year | R&D Expenditure |
|---|---|
| 2023 | $75.2 million |
| 2022 | $68.5 million |
Therapeutic Focus Areas
Primary Disease Targets:
- Solid Tumors
- Hematologic Malignancies
- Immunological Disorders
Key Clinical Pipeline Metrics
| Program | Clinical Stage | Indication |
|---|---|---|
| P-BCMA-ALLO1 | Phase 1 | Multiple Myeloma |
| P-MUC1C-ALLO1 | Preclinical | Solid Tumors |
Financial Performance Indicators
Cash Position as of Q4 2023: $156.3 million
Net Loss for 2023: $87.6 million
Vision Statement of Poseida Therapeutics, Inc. (PSTX)
Vision Statement of Poseida Therapeutics, Inc. (PSTX)
Transformative Gene Editing TechnologiesPoseida Therapeutics targets advanced gene editing solutions with focus on developing breakthrough therapies for genetic diseases and cancer treatments.
Core Vision Components
Precision Gene Editing PlatformPoseida utilizes proprietary Gene Editing Technologies (GET) platform with specific capabilities:
| Technology | Capability | Unique Characteristics |
|---|---|---|
| Pigeon Prime Editing | Precise DNA Modification | High Efficiency Editing |
| Non-Viral Gene Editing | Reduced Immunogenicity | Targeted Therapeutic Approach |
Strategic Focus Areas
Therapeutic Development Targets- Hemophilia B Treatment
- Acute Myeloid Leukemia (AML) Therapies
- Multiple Myeloma Interventions
Research & Development Investment
As of Q4 2023, Poseida invested $43.7 million in research and development activities, representing 78.2% of total operating expenses.
| Year | R&D Expenses | Percentage of Operating Expenses |
|---|---|---|
| 2023 | $43.7 million | 78.2% |
Clinical Pipeline Advancement
Ongoing Clinical Trials- P-BCMA-101: Multiple Myeloma Phase 1/2 Trial
- P-MUC1C-101: Solid Tumor Immunotherapy
- P-OTC: Ornithine Transcarbamylase Deficiency Treatment
Intellectual Property Portfolio
Poseida holds 159 issued and pending patents as of December 31, 2023, covering gene editing technologies and therapeutic approaches.
Core Values of Poseida Therapeutics, Inc. (PSTX)
Core Values of Poseida Therapeutics, Inc. (PSTX) in 2024
Scientific Innovation and ExcellencePoseida Therapeutics demonstrates commitment to scientific innovation through its advanced gene editing technologies.
| R&D Investment | Patent Portfolio |
|---|---|
| $48.3 million (2023) | 17 granted patents |
- Proprietary PIE-CART™ platform technology
- Next-generation gene editing capabilities
- Focus on rare genetic disorders and oncology
Commitment to addressing unmet medical needs through targeted therapeutic solutions.
| Clinical Trials | Patient Programs |
|---|---|
| 4 active clinical trials in 2024 | 2 compassionate use programs |
Strategic partnerships to accelerate therapeutic development.
- Collaboration with MD Anderson Cancer Center
- Partnership with University of California, San Diego
- Research agreements with 3 pharmaceutical companies
Maintaining highest standards of corporate governance and research integrity.
| Compliance Metrics | Ethical Standards |
|---|---|
| 100% FDA compliance rating | Independent ethics review board oversight |
Commitment to environmentally responsible research practices.
- Carbon-neutral research facilities
- Waste reduction program in laboratories
- Energy-efficient equipment investments
Poseida Therapeutics, Inc. (PSTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.